Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors Post published:September 8, 2022 Post category:Press Release
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement Post published:September 8, 2022 Post category:Press Release
atai Life Sciences to Participate in September Investor Events Post published:September 8, 2022 Post category:Press Release
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries Post published:September 7, 2022 Post category:Press Release
Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global Post published:September 7, 2022 Post category:Press Release
BetterLife and Collaborators to Submit Key Joint Research Publication Post published:September 7, 2022 Post category:Press Release
MindMed to Participate in H.C. Wainwright Global Investment Conference USA – English USA – English USA – English Post published:September 7, 2022 Post category:Press Release
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch Post published:September 7, 2022 Post category:Press Release
PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022 Post published:September 7, 2022 Post category:Press Release
Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics Post published:September 6, 2022 Post category:Psychedelic Bulletin